Raya Therapeutics said that it will initiate more amyotrophic lateral sclerosis (ALS) trials in 2025 following the investigator-led Phase II trial data.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,